Enhanced biocompatibility of CD47-functionalized vascular stents. (May 2016)

• Record Type: Journal Article
• Authors: Slee, Joshua B.; Alferiev, Ivan S.; Nagaswami, Chandrasekaran; Weisel, John W.; Levy, Robert J.; Fishbein, Ilia; Stachelek, Stanley J.
• Is Part Of: Biomaterials. Volume 87(2016)
• Page Start: 82
• Page End: 92
• Publication Date: 2016-05
• Subjects: Inflammation -- Bioactive surface coating -- Restenosis -- Platelets -- Bare metal stents -- Signal regulatory protein alpha; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2016.02.008
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: The effectiveness of endovascular stents is hindered by in-stent restenosis (ISR), a secondary re-obstruction of treated arteries due to unresolved inflammation and activation of smooth muscle cells in the arterial wall. We previously demonstrated that immobilized CD47, a ubiquitously expressed transmembrane protein with an established role in immune evasion, can confer biocompatibility when appended to polymeric surfaces. In present studies, we test the hypothesis that CD47 immobilized onto metallic surfaces of stents can effectively inhibit the inflammatory response thus mitigating ISR. Recombinant CD47 (recCD47) or a peptide sequence corresponding to the Ig domain of CD47 (pepCD47), were attached to the surfaces of both 316L-grade stainless steel foils and stents using bisphosphonate coordination chemistry and thiol-based conjugation reactions to assess the anti-inflammatory properties of CD47-functionalized surfaces. Initial in vitro and ex vivo analysis demonstrated that both recCD47 and pepCD47 significantly reduced inflammatory cell attachment to steel surfaces without impeding on endothelial cell retention and expansion. Using a rat carotid stent model, we showed that pepCD47-functionalized stents prevented fibrin and platelet thrombus deposition, inhibited inflammatory cell attachment, and reduced restenosis by 30%. It is concluded that CD47-modified stent surfaces mitigate platelet and inflammatory cell attachment, thereby disrupting ISR pathophysiology.